Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 

 
 

Exhibit (10)(u)    
    

SUMMARY OF COMPENSATION ARRANGEMENTS WITH NON-EMPLOYEE DIRECTORS AS OF January 22, 2008  

        The following summarizes the current compensation and benefits received by the Company's non-employee directors as of January 22, 2008. This
document is intended to be a summary of existing oral, at will arrangements, and in no way is intended to provide any additional rights to any non-employee director. 

Retainer and Meetings Fees 

        The
Board of Directors of Rollins, Inc. (the "Company"), the Board of Directors has approved effective January 1, 2008, the following fee schedule for the Board of
Directors of Rollins, Inc. and all Committees of the Board of Directors of Rollins, Inc. 

	Board of Directors'	 	 
	Quarterly Retainer:	 	$6,000 per quarter to each non-employee Director
	Board Meeting Attended:	 	$1,500 per meeting attended
	

Audit Committee Chairman"	
 	

$4,000 per quarter to the Committee Chairman (in addition to the per meeting fee and a fee of $1,500 for preparation for each quarterly Audit Committee meeting)
	Per Meeting Fee:	 	$2,500 per Audit Committee meeting
	Telephonic Meeting:	 	$1,250 per Audit Committee telephonic meeting
	
Compensation Committee	
 	

 
	Chairman:	 	$2,250 per quarter to the Committee Chairman (in addition to the per meeting fee)
	Per Meeting Fee:	 	$1,500 per Compensation Committee meeting
	
Nominating/Governance Committee	
 	

 
	Chairman:	 	$1,500 per quarter to the Committee Chairman (in addition to the per meeting fee)
	Per Meeting Fee:	 	$1,500 per Nominating/Governance Committee meeting
	
Diversity Committee	
 	

 
	Chairman:	 	$1,500 per quarter to the Committee Chairman (in addition to the per meeting fee)
	Per Meeting Fee:	 	$1,500 per Diversity Committee meeting

        The
above Committee fees are in addition to the fees otherwise payable to directors for service on the Board of Directors of the Company. 

Equity Compensation 

        Under
the terms of the Company's Stock Incentive Plans, directors are eligible to receive stock options, stock awards, and other types of equity-based compensation awards. However, the
Company does not make any such awards to non-employees directors under its current compensation practices. 

        All
non-employee directors are entitled to reimbursement of expenses for all services as a director, including committee participation of special assignments. 

QuickLinks

Exhibit (10)(u)QuickLinks
 -- Click here to rapidly navigate through this document

 

 
 

Exhibit 10.30    
    

MILLENNIUM PHARMACEUTICALS, INC.  

2007 INCENTIVE PLAN  

RESTRICTED STOCK UNIT AGREEMENT  

Number
of Restricted Stock Units awarded to you is set forth in the Notice of Grant of Award and Award Agreement

(the "Notice") provided to you. 

Vesting
Schedule for Restricted Stock Units Awarded: 

	Vesting Date
 
	 	Units Vesting on Vesting Date
 

	As set forth in the Notice	 	As set forth in the Notice

Award
Date is set forth in the Notice 

        Millennium
Pharmaceuticals, Inc. (the "Company") has selected you to receive the Restricted Stock Units award identified above, subject to the provisions of the Millennium
Pharmaceuticals, Inc. 2007 Incentive Plan (the "Plan") and the terms, conditions and restrictions contained in this agreement (the "Agreement"). Please confirm your acceptance of this Award,
and your agreement to the terms of the Plan and this Agreement, by accepting the Award in your online stock plan account with our stock plan administrator. 

MILLENNIUM
PHARMACEUTICALS, INC. 

 

 MILLENNIUM PHARMACEUTICALS, INC.  

2007 INCENTIVE PLAN  

Restricted Stock Unit Agreement  

        1.    Preamble.    This Restricted Stock Unit Agreement contains the terms and conditions of an award of restricted
stock units made to the Recipient pursuant to the Plan. Each restricted stock unit represents the right to receive one share of the Company's common stock, $.001 par value per share subject to certain
restrictions. 

        2.    Restrictions on Transfer.    The Restricted Stock Units may not be sold, transferred, pledged, assigned or
otherwise encumbered or disposed of, whether by operation of law or otherwise, except as specifically provided below. Any attempt to dispose of any Restricted Stock Units in contravention of this
Agreement shall be null and void and without effect. 

        3.    Vesting.    The term "vest" as used in this Agreement means the lapsing of the restrictions that are described
in this Agreement with respect to the Restricted Stock Units. The Restricted Stock Units will vest in accordance with the schedule set forth on the first page of this Agreement, provided in each case
that the Recipient is then, and since the Award Date has continuously been an employee, officer or director of, or consultant or advisor to, the Company or any parent or subsidiary of the Company as
defined in Section 424(e) or (f) of the Code (an "Eligible Participant"). Notwithstanding the foregoing, in the event of the Recipient's death, all Restricted Shares that have not
previously been forfeited will immediately vest, provided that the Recipient was an Eligible Participant at the time of death. 

        4.    Forfeiture.    In the event the Recipient ceases to be an Eligible Participant for any reason, the Restricted
Stock Units that have not previously vested and which do not become vested in accordance with Section 3 of this Agreement, will be automatically and immediately forfeited. 

        5.    Voting Rights and Dividend Equivalents.    The Recipient will not be entitled to any voting rights of a
shareholder of the Company's common stock. To the extent provided by the Board, in its sole discretion, a grant of Restricted Stock Units may provide the Recipient with the right to receive an amount
equal to any dividends or other distributions declared and paid on an equal number of outstanding shares of the Company's common stock ("Dividend Equivalents"). Dividend Equivalents may be paid
currently or credited to an account for the Recipient, may be settled in cash and/or shares of common stock and may be subject to the same restrictions on transfer and forfeitability as the Restricted
Stock Units with respect to which paid, as determined by the Board in its sole discretion. 

        6.    Conversion of Restricted Stock Units; Issuance of Common Stock.    The time of distribution of common stock
represented by the Restricted Stock Units is set forth in the Notice. As soon as practicable following the time of distribution of any Restricted Stock Units, the Company will cause to be issued and
delivered to the Recipient shares of the Company's common stock in payment of the vested Restricted Stock Units, subject to the payment by the Recipient by cash or other means acceptable to the
Company (or directly to such taxing authorities as appropriate) of federal, state, local and other applicable taxes required to be withheld in connection with such distribution, if any. The Recipient
understands that once the shares of common stock have been delivered to the Recipient in respect of Restricted Stock Units which have vested, the Recipient will be free to sell the shares of common
stock, subject to applicable requirements of federal and state securities laws and Company policies. 

        7.    Taxes.    The Recipient acknowledges and agrees that the Recipient is solely responsible for any and all taxes
that may be assessed by any taxing authority arising in any way out of the award of Restricted Stock Unit and that the Company is not liable for any such assessments. The grant and the vesting of the
Restricted Stock Units, and the payment of dividends with respect to the Restricted Stock Units, may give rise to taxable income subject to withholding. The Recipient acknowledges and 

2

 

agrees
that the Recipient is aware of and understands the tax consequences to the Recipient of this Agreement. 

        8.    Administration.    The Board of Directors of the Company, or the Compensation and Talent Committee of the Board
of Directors or other committee designated in the Plan or by the Board of Directors, has the authority to manage and control the operation and administration of this Agreement. Any interpretation of
the Agreement by such body and any decision made by it with respect to the Agreement is final and binding. 

        9.    Plan Terms and Definitions.    Notwithstanding anything in this Agreement to the contrary, the terms of this
Agreement are subject to the terms of the Plan, a copy of which has already been provided to the Recipient. Capitalized terms used herein and not otherwise defined shall have the meaning ascribed to
them in the Plan, as the same may be amended from time to time and as in effect on the date of determination. 

        10.    Amendment.    This Agreement may be amended only by written agreement between the Recipient and the Company. 

3

QuickLinks

Exhibit 10.30QuickLinks
 -- Click here to rapidly navigate through this document

 

 
 

Exhibit 10.54    
    

[Millennium logo]

MILLENNIUM PHARMACEUTICALS, INC.  

September 30,
1997

REVISED
OFFER

Ms. Anna
Protopapas

1 Cazenove Street

Boston, MA 02116 

Dear
Anna, 

        This
letter supersedes and replaces our original offer letter sent to you, dated September 29, 1997. 

        On
behalf of Millennium Pharmaceuticals, Inc. (the "Company"), I am pleased to offer you the position of Director, Business Development in the Business Development group reporting
to Alan Crane, Vice President, Business Development. 

        1.    Job Responsibilities:    Your job responsibilities in this position will include the following: 

	•
	Work
with research to identify, analyze, and prioritize opportunities outside of health care to build value and realize near-term products using Millennium
technologies.

	•
	Coordinate
presentations and discussions with potential partners.

	•
	Act
as lead or co-lead negotiator on major strategic alliances.

	•
	Work
with research and business personnel to forge new strategic alliances with pharmaceutical companies relating to Millennium's technology platform and to disease areas.

	•
	Actively
participate in development of the Company's strategic plans.

	•
	Serve
as an internal and external spokesperson for the Company's business strategy and technologies.

	•
	Develop
strong working relationships with other groups in the Company to ensure teamwork on all projects.

	•
	Actively
participate in recruiting only the best scientific and management team for Millennium. 

        2.    Effective Date:    The effective date of your full-time employment with the Company is to be
determined upon your formal acceptance of this offer. 

        3.    Salary:    Your base salary will initially be $135,000 per annum. Your salary will be paid periodically in
accordance with the Company's payroll procedures. In addition, you will receive, no less frequently than
annually, a salary review which will be based on your performance, the Company's performance and such other factors as may be determined by the Company's Board of Directors. 

        4.    Benefits:    You and your dependents will be eligible for the Company's standard medical, dental, life
insurance, disability benefits and Section 125 cafeteria plan. After the standard waiting periods, you will also be eligible to participate in the Company's 401(k) and Employee Stock Purchase
plans. You will accrue vacation at the rate of 1.25 days per month of full-time employment. Standard paid holidays will be observed. Transportation benefits, including a choice of
MBTA pass or off-site parking, are also available. The Company, however, reserves the right to modify its employee benefit programs from time-to-time. 

        5.    Equity Participation, Vesting of Stock:    Subject to approval by the Company's Board of Directors, you will be
granted an incentive stock option exercisable for 25,000 shares of the Company's 

 

Common
Stock at an exercise price equal to the current fair market value of the Company's Common Stock as determined by the Company's Board of Directors. This option will vest as to one fourth
(1/4) of the shares on the first anniversary of your commencement of full-time employment with the Company and as to one forty-eighth (1/48) of the shares at
the end of each full month thereafter until all shares are vested, provided that you remain employed by the Company. In the event of your death or total and permanent disability (as defined in the
Internal Revenue Code of 1986, as amended) during the first year of your employment, the initial one-fourth (1/4) of your shares that would have vested at the end of your
first year of employment shall vest. In the event of termination of your employment for any reason (except as set forth in the preceding sentence), vesting shall cease. Please refer to the Company's
Incentive Stock Plan for complete details. 

        6.    Employment Period:    Your employment with the Company will be at-will, meaning that you will not be
obligated to remain employed by the Company for any specified period of time; likewise, the Company will not be obligated to continue your employment for any specific period and may terminate your
employment at any time, with or without cause. 

        7.    Employment Eligibility Verification:    Please note that all persons employed in the United States, are required
to complete an Employment Eligibility Verification Form on the first day of employment and submit an original document or documents that establish identity and employment eligibility within three
business days of employment. For your convenience, we are enclosing Form I-9 for your review. You will need to complete Section 1 and present original document(s) of your
choice as listed on the reverse side of the form once you begin work. 

        8.    Proprietary Information, No Conflicts:    You agree to execute the Company's standard form of Invention,
Non-Disclosure and Non-Competition Agreement and to be bound by all of the provisions thereof. You hereby represent that you are not presently bound by any employment
agreement, confidential or proprietary information agreement or similar agreement with any current or previous employer that would impose any restriction on your acceptance of this offer or that would
interfere with your ability to fulfill the responsibilities of your position with the Company. 

        9.    Medical Surveillance:    As part of Millennium's medical surveillance program, all laboratory employees are
required to have an initial physical, provided at Mt. Auburn Hospital. All laboratory employees working with hazardous chemical, infectious agents, radio labeled materials or animals shall have access
to medical attention, including initial and periodic medical exams without cost to the employee or loss of pay. An employee may refuse an exam if he/she signs a release. If you want to decline from
having the initial physical, please notify Shelly Adler at (617) 679-7106 prior to your start date. Your initial surveillance examination will be scheduled to take place on the
first day of your employment. 

        10.    Sign-on Bonus:    The Company will pay you a bonus of $7,500 on the date of the first paycheck
following commencement of your full time employment. Should you terminate for any reason within 12 months of your starting date after having received your bonus, the Company reserves the right
to seek repayment of all or a pro-rata portion of your bonus. 

2

 

        Anna,
all of us here at Millennium are very enthusiastic about your commitment to joining the Company and have the highest expectation of your future contributions. 

        Please
indicate your acceptance of the foregoing by signing the enclosed copy of this letter and returning it to the Company no later than October 7, 1997. After that date, the
offer will lapse. 

Very
truly yours,

MILLENNIUM PHARMACEUTICALS, INC. 

	/s/  LINDA K. PINE      
 LINDA K. PINE

Vice President, Human Resources	 	 
	

The foregoing is signed and accepted as of the date first above written by:
	

/s/  ANNA PROTOPAPAS      
 Anna Protopapas	
 	

October 1, 1997
 Date

3

QuickLinks

Exhibit 10.54

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00137-of-00352.parquet"}]]